Registry of antithrombotic therapy in atrial fibrillation patients with bioprosthetic valves: A retrospective observational study.

CONCLUSIONS: In a current real-world setting in Japan, warfarin was the most commonly used treatment in AF patients with bioprosthetic valves, but there was an increasing trend of DOAC-treated patients. Further investigations are needed to confirm the efficacy and safety of DOAC in patients with bioprosthetic valves. PMID: 32156512 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32156512?dopt=Abstract

Source: Journal of Cardiology - March 6, 2020 Category: Cardiology Authors: Izumi C, Miyake M, Amano M, Kitai T, Obayashi Y, Takegami M, Kimura T, Sugio K, Matsumoto T, Nishimura K, Furukawa Y Tags: J Cardiol Source Type: research